Abstract
Previously, we have reported short term effectiveness and safety of dupilumab in Korea. In this study, we are trying to report the long-term effectiveness and safety of dupilumab in Korea. Ninety-nine patients with moderate to severe AD were analyzed. They were evaluated using Eczema Area and Severity Index (EASI), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) at baseline, week 16, 32 and 52. Efficacy outcomes showed higher improvement at 52 weeks compared with 16 weeks; high percentual reductions in EASI (88.1%), peak pruritus NRS (65.6%), POEM (67.2%), and DLQI (69.0%) compared to baseline. Proportion of patients achieving EASI 75 and 90 were 90.2% and 53.7%. POEM and DLQI had high correlation with clinical measured outcomes. In the analysis for the factors affecting achievement of EASI 90, female gender (OR 2.5), eosinophilia (OR 0.2) and elevated LDH (OR 0.07) were significantly associated. Most frequent adverse events included facial erythema (19.2%) and conjunctivitis (17.2%), which were mild/moderate and resolved during treatment. In conclusion, dupilumab treatment for 52 weeks in Korean patients with moderate-to-severe AD confirmed long term effectiveness and safety.
Highlights
We have reported short term effectiveness and safety of dupilumab in Korea
This retrospective analysis was conducted through electronic medical records of patients with moderate to severe Atopic dermatitis (AD) treated with dupilumab at National Medical Center in Korean from September 2018 to December 2020
This study showed a higher efficacy than the existing clinical trials and other real-world studies8–14; 88.58% of patients achieved significant improvements in Eczema Area and Severity Index (EASI) at week 52 in this study, compared to 78.3% in LIBERTY AD CHRONOS, and 76.38% in United Kingdom (UK) real-world data
Summary
We have reported short term effectiveness and safety of dupilumab in Korea. Dupilumab treatment for 52 weeks in Korean patients with moderate-to-severe AD confirmed long term effectiveness and safety. Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-137, is a first biological agent approved for the treatment of patients with moderate to severe AD. Until recently, it has been most actively used and considered as a game changer in the treatment of severe AD. We aimed to evaluate the long-term effectiveness and safety of 52 weeks of treatment with dupilumab in moderate to severe AD patients in Korea and investigate the prognostic factors affecting the treatment outcome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.